when will retatrutide be available in usa Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners clinics across the country are prescribing it anyway, a CBS News investigation Learn about Retatrutide Medication |
Description
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist that activates both GIP and GLP-1 receptors, whereas traditional GLP-1 receptor agonists such as semaglutide and liraglutide target only the GLP-1 pathway

They will conduct a detailed assessment and recommend the most suitable treatment plan based on your health condition

Measurable weight loss becomes apparent by week 2 to 3 for the majority of individuals

Dimensions: 1.5 2.75 1 in

Some patients and clinicians have explored combining ketogenic diets with prescription GLP-1 receptor agonist therapy, though this approach requires careful medical supervision

not a drug or dietary supplement